PDF(815 KB)
PDF(815 KB)
PDF(815 KB)
晚期非小细胞肺癌患者化疗用药合理性评估
Rationality assessment of postoperative chemotherapy in patients with advanced non-small cell lung cancer
目的：评价晚期非小细胞肺癌患者药物治疗方案的合理性，以期为临床合理用药提供参考。方法：收集2014年4月—2015年3月某院收治的120例非小细胞肺癌患者资料，统计患者化疗方案、辅助用药、治疗过程监测以及化疗相关不良反应情况。结果：120例患者共使用11种含铂两药化疗方案，以吉西他滨联合奈达铂的治疗方案用药频度最高，构成比为28.08%。有43例次化疗中，一种化疗药超剂量使用。6种辅助用药DUI>1。中药注射剂与止吐药用药频度最高，分别为3 754.8 DDD和3 985.0 DDD。盐酸托烷司琼注射液、注射用埃索美拉唑和和痰热清注射液的药物利用指数居前三位，分别为1.8、1.4和1.4。在药物选择、给药剂量、配置浓度以及异常检验指标的复查方面，存在一些有待改进之处。结论：某院晚期非小细胞肺癌的药物治疗方案基本贯彻指南要求，但在给药剂量、治疗过程监测、中药注射剂的使用方面仍需进一步规范。
OBJECTIVE To evaluate the medication rationality in postoperative chemotherapy patients with advanced non-small cell lung cancer (NSCLC),provide evidences for rational medication.METHODS Data of 120 patients with advanced NSCLC were collected,who were inpatients from April 2014 to March 2015.The medication of chemotherapy regimens,the adjuvant drugs,the therapeutic process monitoring and adverse drug reactions (ADRs) were analyzed retrospectively with the methods of drug use evaluation (DUE) and drug use review (DUR).RESULTS Eleven kinds of two-drug regimens involving platinum were used to treat 120 patients.Gemcitabine together with nedaplatin was used most frequently,accounting for 28.08%.Forty three cases of overdose occurred.Among adjuvant drugs,DUI of 6 drugs was more than 1.The utilization frequencies of Traditional Chinese Medicine (TCM) injections and antiemetic medicine were high,up to 3 754.8 DDD and 3 985 DDD,respectively.The DUI values of tropisetron hydrochloride injection,esomeprazole injection and Tanreqing injection were the top three,up to 1.8,1.4 and 1.4.It was necessary to improve the rationality of drug selection,dosage,concentration and the review of abnormal indicators.CONCLUSION Medication treatment of advanced NSCLC in the hospital should be implemented according to the guidelines basically.Meanwhile,the dosage,the therapeutic process monitoring and the use of Traditional Chinese Medicine still need to be improved in the future.
非小细胞肺癌 / 化疗方案 / 辅助用药 / 合理性评价 {{custom_keyword}} /
non-small cell lung cancer / postoperative chemotherapy / adjuvant medicine / rationality assessment {{custom_keyword}} /
[1] Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:Non-Small Cell Lung Cancer.V.2.2013[EB/OL].http://www.nccn.org./prottesionals/physician_gls/PDF/nscl.pdf.2013-01-17/2013-06-13.
[3] 王静,阎瑞峰.紫杉醇联合卡铂或奥沙利铂治疗晚期非小细胞肺癌的临床疗效观察[J].山西医药杂志,2015,44(13):1546-1548.
[4] 焦安娜,沈丽琴,庄志祥.培美曲塞单药或联合顺铂二线治疗晚期非小细胞肺癌52例临床观察[J].临床合理用药,2010,3(5):11-12.
[5] 国家药典委员会.中国药典临床用药须知[M].北京:中国医药科技出版社,2010:341-1140.
[6] 陈新谦,金有豫,汤光.新编药物学[M].北京:人民卫生出版社,1992:460-799.
[7] 邹大进.糖尿病治疗中的药物经济学[J].中华医学信息导报,2003,18(24):18.
[8] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®):Non-Small Cell Lung Cancer.Version 1.2017-October 14,2016[EB/OL].http://www.nccn.org/patients
[9] 国家中医药管理局.中成药临床应用指导原则(国中医药医政发
[2010] 30号)[EB/OL].http://http://www.satcm.gov.cn/e/action/ShowInfo.php?classid=26&id=10176.
[10] 国家中医药管理局.关于进一步加强中药注射剂生产和临床使用管理的通知.(卫医政发
[2008] 71)[EB/OL].http://www.sda.gov.cn/WS01/CL0056/35302.html.
[11] Heon S,Johnson BE.Adjuvant chemotherapy for surgically resected non-small cell lung cancer[J].J Thorac Cardiovasc Surg,2012,144(3):S39-S42.
[12] Sangha R,Price J,Butts CA.Adjuvant therapy in non-small cell lung cancer:current and future directions[J].Oncologist,2010,15(8):862-872.
[13] Takigawa N,Segawa Y,Ueoka H,et al.Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer[J].Cancer Chemother Pharmacol,2000,46(4):272-278.
[14] Desoize B,Madoulet C.Particular aspects of Platinum compounds used at present in cancer treatment[J].Crit Rev Oncol Hematol,2002,42(3):317-325.
[15] Kanzawa F,Koizumi F,Koh Y,et al.In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase Ⅰ inhibitor irinotecan and the mechanism of this interaction[J].Clin Cancer Res,2001,7(1):202-209.
[16] 罗阳超.吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效观察[J].中国实用内科杂志,2015,35(1):71-72.
[17] 姚舒洋,钱坤,胡牧,等.吉西他滨联合奈达铂或卡铂一线治疗晚期非小细胞肺癌的疗效及安全性[J].中国医学前沿杂志(电子版),2015,7(2):18-21.
[18] 罗德诚,陈文彬.临床药物治疗学[M].北京:人民卫生出版社,2000:343.
[19] 钱南萍,魏润新,许静,等.临床药师对肿瘤化疗患者的用药教育[J].中国药房,2012,23(10):951-953.
[20] Shi MQ,Shen B,Cao GC,et al.Comparison of efficacy and toxicity between gemcitabine plus cisplatin and plus carboplatin in first-line treatment of advanced non-small cell lung cancer[J].Chin German J Clin Oncol,2008,7(4):196-199.
[21] 鲁会侠,罗俊,冯锁民.临床药师在肺癌化疗方案执行过程中应关注的问题[J].儿科药学杂志,2012,18(8):61-63.
[22] 沈宇舟,潘旭峰,赵珩.非小细胞肺癌术后化疗患者药物利用调查[J].中国药师,2014,17(2):293-295.
[23] Wiser W,Berger A.Practical management of chemotherapy-induced nausea and vomiting[J].Oncology (Williston Park),2005,19(5):637-645.
[24] 中国抗癌协会癌症康复与姑息治疗专业委员会,中国临床肿瘤学会抗肿瘤药物安全管理专家委员会.(ASMC).肿瘤治疗相关呕吐防治指南(2014版)[J].临床肿瘤学杂志,2014,19(3):263-273.
[25] Basch E,Prestrud AA,Hesketh PJ,et al.Antiemetics:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol,2011,29(31):4189-4198.
[26] 陆磊,周秋云,钱智磊,等.2014-2015 年南京市胸科医院肺癌化疗辅助用药的使用情况分析[J].现代药物与临床,2016,31(1):101-105.
[27] 徐小燕.2010 年南京地区抗肿瘤中药注射剂应用分析[J].中国医院用药评价与分析,2011,11(12):1089-1091.
[28] 美国卫生及公共服务部.常见不良事件评价标准(CTCAE)V4[Z],出版年度缺失:03.
江苏省药学会医院药学科研基金（编号：201311）
/
| 〈 |
|
〉 |
